银杏蜜环口服溶液联合达比加群酯治疗老年ACS的临床疗效

Clinical Efficacy of Yinxing Mihuan Oral Solution Combined with Dabigatran Etexilate in the Treatment of ACS in the Elderly

摘要: 目的：评价银杏蜜环口服溶液联合达比加群酯治疗老年ACS (急性冠脉综合症)患者的临床疗效及对血脂、肌酸激酶、血小板聚集率等相关生化指标的影响。方法：选取老年ACS患者136例，依据治疗方案分为对照组(应用达比加群酯)和治疗组(加用银杏蜜环口服溶液)，观察两组患者治疗前后肌酸激酶、血小板聚集率及总胆固醇、甘油三酯、低密度脂蛋白的变化情况及临床疗效。结果：相对于对照组，治疗组治疗后，TC、TG、LDL-C、CK、PAR值均显著降低，P < 0.05，差异有统计学意义(P值分别为：0.047，0.028，0.011，0.004，0.000)。治疗组总有效率高于对照组，且差异有统计学意义(P = 0.049)。结论：银杏蜜环口服溶液联合达比加群酯治疗老年ACS能明显缓解患者心肌缺血症状，提高临床疗效，同时可以降低患者血脂水平，减缓动脉粥样硬化进程，临床值得推广应用。

Abstract: Objective: To evaluate the clinical efficacy of Yinxing Mihuan oral solution combined with Dabigatran Etexilate in the treatment of elderly patients with ACS (acute coronary syndrome) and the effects on the related biochemical indexes such as blood lipids, CK (creatine kinase) and PAR (platelet aggregation rate). Methods: One hundred and thirty-six elderly patients with ACS who were treated in the Department of Cardiology were selected and divided into a treatment group and a control group, respectively. The control group was treated with Dabigatran Etexilate etc., and the treatment group was treated with Yinxing Mihuan oral solution on basis of control group. The changes of CK, PAR (platelet aggregation rate), TC (total cholesterol), TG (triacylglycerol), LDL-C (low density lipoprotein) and the clinical efficacy of the two groups were observed before and after treatment. Results: Compared with the control group, TC, TG, LDL-C, CK, and PAR values were signif-icantly lower in the treatment group with a statistically significant difference, P < 0.05 (P values: 0.047, 0.028, 0.011, 0.004, and 0.000, respectively). The total effective rate of the treatment group was higher than that of the control group, and the difference was statistically significant (P = 0.049). Conclusions: Yinxing Mihuan oral solution combined with Dabigatran Etexilate can apparently im-prove patients’ blood lipid level, slow down the process of atherosclerosis, relieve patients’ symp-toms of myocardial ischemia, and improve clinical efficacy in the treatment of elderly ACS, which is worthy of clinical application.